Zoetis
ZTS
$119.04
-1.42%
Zoetis Inc. is a global leader in the animal health industry, specializing in the development, manufacturing, and commercialization of medicines, vaccines, diagnostics, and other health products for both companion animals (like dogs, cats, and horses) and livestock. As the largest market share holder, spun off from Pfizer, its competitive identity is that of a dominant, diversified platform company with a significant skew towards the higher-margin and resilient companion animal segment, particularly in the U.S. The current investor narrative is intensely focused on the company's growth trajectory, as recent quarterly results have sparked debate; while the company issued strong forward guidance, analysts are questioning its competitive positioning and pathway to sustained growth amid reported declines in key business segments.…
ZTS
Zoetis
$119.04
Related headlines
ZTS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $154.75 and implied upside of +30.0% versus the current price.
Average Target
$154.75
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$95 - $155
Analyst target range
Analyst coverage appears limited with only 6 analysts providing estimates, and the institutional ratings data shows a recent shift towards caution, including a downgrade from Piper Sandler from Overweight to Neutral in January 2026. The consensus sentiment leans neutral-to-bullish but is tempered, with recent actions including reiterations of Buy (BTIG), Overweight (Morgan Stanley, JP Morgan), and Hold/Neutral ratings from others, indicating a lack of strong conviction for a near-term rebound. The target price range implied by EPS estimates is tight, with a low of $9.12, an average of $9.27, and a high of $9.47, but without explicit price targets, the implied upside is unclear; the wide dispersion in recent analyst actions (downgrades alongside maintained buys) and the limited number of covering analysts signals higher uncertainty and potentially less efficient price discovery for this large-cap stock.
Bulls vs Bears: ZTS Investment Factors
The bear case currently holds stronger evidence, driven by concrete deterioration in fundamental metrics: growth has decelerated to a low single-digit pace, margins are compressing, and the stock is in a severe technical downtrend. The bull case rests on the company's defensive market leadership, strong cash flow, and a valuation that has already de-rated significantly from historical peaks. The single most important tension in the investment debate is whether the recent margin pressure and growth slowdown are transient issues or signs of a sustained competitive and operational deterioration. The resolution of this tension, evidenced by future quarterly gross margin stability and revenue re-acceleration, will determine if the stock is a value trap or a compelling turnaround opportunity.
Bullish
- Strong Free Cash Flow Generation: The company generated $2.283 billion in trailing twelve-month free cash flow, providing significant financial flexibility. This robust cash generation supports the dividend (1.59% yield), debt service, and internal reinvestment without reliance on external capital.
- Defensive Business Model & Market Leadership: As the global leader in animal health, Zoetis benefits from a resilient, non-cyclical demand base, with ~65% of revenue from companion animals. This defensive skew, particularly in the U.S., provides a stable earnings foundation even in economic downturns.
- Attractive Forward Valuation Compression: The stock's forward P/E of 15.61x represents a significant discount to its own historical multiples, which have exceeded 40x. This de-rating suggests much of the growth disappointment is already priced in, offering a more reasonable entry point for a market leader.
- Healthy Balance Sheet & Liquidity: Despite a high debt-to-equity ratio of 2.85, the company maintains a strong current ratio of 3.03 and ample liquidity. This financial strength mitigates near-term solvency risks and provides a buffer against operational headwinds.
Bearish
- Severe Growth Deceleration & Segment Weakness: Q4 2025 revenue of $2.387B grew only 3.02% YoY and declined sequentially from Q3. Recent news highlights declining growth in key segments, directly challenging the core thesis of steady, defensive growth and raising questions about competitive positioning.
- Pronounced Margin Compression: Gross margin fell to 68.87% in Q4 2025 from 72.28% in Q2 2025, while operating income dropped from $989M to $826M over the same period. This indicates rising costs or pricing pressures are eroding the company's historically strong earnings power.
- Sustained Technical Downtrend & Underperformance: The stock is down 19.82% over the past year and trades just 4.0% above its 52-week low of $113.29. It has severely underperformed the S&P 500 by -49.34% over the past year, reflecting deep bearish sentiment and a lack of positive catalysts.
- Elevated Valuation vs. Peers: Despite the recent sell-off, Zoetis trades at a premium to its sector with a forward P/E of 15.61x, P/S of 5.89x, and EV/EBITDA of 15.48x. If growth continues to slow, these multiples are vulnerable to further compression.
ZTS Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 19.82% over the past year. Currently trading at $117.86, it sits just 4.0% above its 52-week low of $113.29, positioning it near the bottom of its annual range, which signals deep bearish sentiment and potential oversold conditions, though it risks being a 'falling knife' if fundamentals continue to deteriorate. Recent momentum shows no signs of a meaningful reversal, with the stock down 7.32% over the last three months and a further 1.61% over the past month, indicating persistent selling pressure that aligns with the longer-term downtrend. The stock's beta of 0.974 suggests its volatility is roughly in line with the broader market, but its severe underperformance is stark, evidenced by a relative strength of -49.34% versus the S&P 500 over the past year. Key technical levels are clearly defined, with immediate support at the 52-week low of $113.29 and formidable resistance far above at the 52-week high of $172.23; a decisive break below support could trigger another leg down, while any recovery would need to overcome significant overhead supply, with the stock's current positioning near multi-year lows reflecting a high degree of investor pessimism.
Beta
0.97
0.97x market volatility
Max Drawdown
-33.4%
Largest decline past year
52-Week Range
$113-$172
Price range past year
Annual Return
-18.9%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -2.2% | +4.6% |
| 3m | -4.5% | +1.4% |
| 6m | -17.4% | +5.6% |
| 1y | -18.9% | +33.5% |
| ytd | -5.5% | +2.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Revenue growth has decelerated and turned negative on a sequential basis, with Q4 2025 revenue of $2.387 billion representing a modest 3.02% year-over-year increase but a decline from the $2.400 billion reported in Q3 2025. The multi-quarter trend shows volatility, with revenue dipping from $2.460 billion in Q2 2025, indicating potential softness in demand or competitive pressures, which directly challenges the core investment thesis of steady, defensive growth. Profitability remains robust but is showing signs of margin compression; the company reported net income of $603 million in Q4 with a gross margin of 68.87%, yet this gross margin has declined from 72.28% in Q2 2025, and operating income of $826 million in Q4 is down from $989 million in Q2, suggesting rising costs or pricing pressures are impacting earnings power. The balance sheet is leveraged but supported by strong cash generation; the debt-to-equity ratio is elevated at 2.85, indicating significant financial leverage, but this is mitigated by substantial free cash flow of $2.283 billion (TTM) and a healthy current ratio of 3.03, providing ample liquidity to service debt and fund operations internally without immediate reliance on external capital.
Quarterly Revenue
$2.4B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.68%
Latest Quarter
Free Cash Flow
$2.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
Given a positive net income of $603 million in the latest quarter, the primary valuation metric is the P/E ratio. The trailing P/E stands at 20.87x, while the forward P/E is notably lower at 15.61x, indicating the market expects a meaningful rebound in earnings, likely aligning with the company's provided guidance for 2026. Compared to sector averages, Zoetis trades at a significant premium; its forward P/E of 15.61x is above the typical range for specialty pharmaceuticals, and its Price-to-Sales ratio of 5.89x and EV/EBITDA of 15.48x are also elevated, suggesting the market continues to price in its industry-leading position and the defensive nature of its cash flows despite recent growth concerns. Historically, the current trailing P/E of 20.87x sits well below its own 5-year highs, which have exceeded 40x, indicating a substantial de-rating has already occurred; this compression reflects the market's adjustment to lower growth expectations, positioning the stock in a more reasonable, if not yet cheap, valuation zone relative to its own history.
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 22x~70x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on deteriorating fundamentals. Revenue growth has slowed to 3.02% YoY in Q4 2025 and turned sequentially negative, indicating potential market share loss or demand softness. Concurrently, gross margin compression from 72.28% to 68.87% over two quarters signals rising costs or an inability to maintain pricing power, directly threatening the high-margin companion animal business that constitutes 65% of sales. While strong free cash flow of $2.283B TTM and a current ratio of 3.03 provide a liquidity cushion, the elevated debt-to-equity ratio of 2.85 adds financial risk if earnings continue to decline.
Market & Competitive Risks are heightened by the stock's premium valuation and weak sentiment. Despite a 20% price decline, Zoetis's forward P/E of 15.61x and EV/EBITDA of 15.48x remain above sector averages, leaving it exposed to multiple compression if growth fails to re-accelerate. The beta of 0.974 indicates market-correlated volatility, but the stock's -49.34% relative strength versus the S&P 500 shows unique, company-specific negative momentum. Recent analyst downgrades (e.g., Piper Sandler to Neutral) and news questioning its 'pathway to growth' highlight emerging skepticism about its competitive moat and ability to fend off rivals in key segments.
The Worst-Case Scenario involves a continuation of the current negative trends: sequential revenue declines persist, margin compression accelerates due to competitive or cost pressures, and the company misses its own 2026 guidance. This could trigger a wave of analyst downgrades and a further de-rating of its premium multiples. A realistic downside target aligns with the 52-week low of $113.29, representing a -4% decline from the current price of $117.86. A more severe bear case, factoring in a return to sector-average multiples, could see a drawdown approaching the stock's maximum observed drawdown of -34.02%, implying a potential loss of over -30% from current levels.